2012
DOI: 10.1056/nejmc1206221
|View full text |Cite
|
Sign up to set email alerts
|

Insulin-Pump Therapy for Type 1 Diabetes Mellitus

Abstract: How to citeComplete issue More information about this article Journal's homepage in redalyc.org Scientific Information System Network of Scientific Journals from Latin America, the Caribbean, Spain and Portugal Non-profit academic project, developed under the open access initiative

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
1
0
1

Year Published

2016
2016
2021
2021

Publication Types

Select...
3
3
1

Relationship

0
7

Authors

Journals

citations
Cited by 8 publications
(2 citation statements)
references
References 22 publications
(20 reference statements)
0
1
0
1
Order By: Relevance
“…Diabetes mellitus is divided into type 1 diabetes mellitus which is insulin-dependent and type 2 which is non-insulin-dependent. Type 1 is manifested due to the destruction of pancreatic beta cells which leads to the release of low insulin into the blood and it can be regulated by the administration of insulin (23). Whereas type 2 occurs when insulin is not used properly by the body or the body reaction with insulin production is reduced (24).…”
Section: Antidiabetic Activitymentioning
confidence: 99%
“…Diabetes mellitus is divided into type 1 diabetes mellitus which is insulin-dependent and type 2 which is non-insulin-dependent. Type 1 is manifested due to the destruction of pancreatic beta cells which leads to the release of low insulin into the blood and it can be regulated by the administration of insulin (23). Whereas type 2 occurs when insulin is not used properly by the body or the body reaction with insulin production is reduced (24).…”
Section: Antidiabetic Activitymentioning
confidence: 99%
“…Diversos meta-análisis randomizados que comparan MDI frente a ICSI, concluyen que la ICSI consigue mejor control glucémico que la insulinización mediante MDI [55], [56], aunque con una diferencia muy discreta (de -0,2 a -0,4% puntos). Además, la mejora del control glucémico se consigue con una menor cantidad de insulina, habiéndose descrito una reducción media de las necesidades de insulina del 14% en los pacientes que usan ISCI comparados con los tratados con MDI, y una reducción de la frecuencia de las hipoglucemias graves, tanto por la farmacocinética de la insulina suministrada como por la reducción de la dosis de insulina [57].…”
Section: Insulinoterapiaunclassified